#Vienna #Austria #Coreline Soft #AVIEW #Lung Cancer Screening

Coreline Soft Introduces AVIEW AI Technology at ECR 2025

Coreline Soft, a leading firm in medical AI, is set to showcase its innovative AVIEW at the upcoming European Congress of Radiology (ECR) 2025, scheduled from February 26 to March 2. This pivotal event will take place at the Austria Center in Vienna, bringing together radiologists and medtech companies from across the globe.

The ECR 2025 represents a significant platform for Coreline Soft to present its revamped AVIEW product lineup, especially the AVIEW (LCS Plus). The focus of this launch is on enhancing lung cancer screening practices across Europe through advanced technology and effective collaboration.

In recent months, various European nations have initiated or progressed with lung cancer early detection projects, emphasizing the implementation of AI diagnostic tools and innovative workflows. Coreline Soft has established credibility in this domain by participating in significant lung cancer screening initiatives, showcasing its ability to manage cloud-based AI imaging data and execute large-scale screenings efficiently. The evolution of AVIEW into its next generation stems from the synthesis of past experiences and research, aiming for an accelerated presence in the European market.

The latest iteration of AVIEW emphasizes optimized efficiency grounded in robust security and stability. It intelligently extracts and utilizes crucial data via an enhanced user interface (UI) and user experience (UX), thereby innovating the communication capabilities within the application.

Coreline Soft has indicated that in an era where AI innovations and workflow automation are critical, seamless collaboration solutions represent vital competitive advantages. Drawing from experiences amassed through the European Lung Cancer Screening Project (4ITLR), and participation in initiatives in Germany (HANSE) and Italy (RISP), the upcoming product is poised to elevate lung cancer screening paradigms.

Following the success of the HANSE project in Germany, the country has advocated for AI as a primary diagnostic tool in lung cancer screenings, with similar movements observed in major European territories, including France. A relevant publication in the European Journal of Cancer has asserted that AVIEW LCS can serve as a primary reader device for lung cancer prevention initiatives.

Coreline Soft aims to expedite the distribution of AI diagnostic solutions in line with the broader rollout of lung cancer screening across Europe. Key certifications have recently been achieved, including compliance with the European General Data Protection Regulation (GDPR) to enhance their global market impact. According to Jason (Junghyuck) Suh, Overseas Business Director at Coreline Soft, their optimal AI solutions, characterized by precision, speed, and collaborative capabilities, will continue to expand their influence.

Overall, the demonstration of AVIEW at ECR 2025 not only highlights Coreline Soft's commitment but also sets a benchmark for future advancements in medical diagnostics, particularly in lung cancer screening.



For further updates, stay tuned to Coreline Soft's announcements as they prepare to reshape the landscape of lung cancer diagnostics in Europe.